Last reviewed · How we verify
Prevenar 13 and Synflorix
Prevenar 13 and Synflorix are pneumococcal conjugate vaccines that stimulate the immune system to produce antibodies against Streptococcus pneumoniae serotypes.
Prevenar 13 and Synflorix are pneumococcal conjugate vaccines that stimulate the immune system to produce antibodies against Streptococcus pneumoniae serotypes. Used for Prevention of invasive pneumococcal disease caused by susceptible serotypes, Prevention of pneumococcal pneumonia, Prevention of pneumococcal otitis media.
At a glance
| Generic name | Prevenar 13 and Synflorix |
|---|---|
| Also known as | Synflorix(R), PCV10, Prevenar 13(R), PCV13 |
| Sponsor | Papua New Guinea Institute of Medical Research |
| Drug class | Pneumococcal conjugate vaccine |
| Target | Streptococcus pneumoniae polysaccharide antigens (serotype-specific) |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
These vaccines contain polysaccharide antigens from different serotypes of S. pneumoniae conjugated to protein carriers, which enhances immunogenicity and T-cell dependent responses. The vaccines prime the adaptive immune system to recognize and neutralize pneumococcal pathogens, providing protection against invasive pneumococcal disease and pneumonia. Prevenar 13 covers 13 serotypes while Synflorix covers 10 serotypes, with some overlap and differences in serotype coverage.
Approved indications
- Prevention of invasive pneumococcal disease caused by susceptible serotypes
- Prevention of pneumococcal pneumonia
- Prevention of pneumococcal otitis media
Common side effects
- Injection site erythema
- Injection site swelling
- Injection site pain
- Fever
- Irritability
- Drowsiness
Key clinical trials
- Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine When Co-administered With Routine Pediatric Vaccines in Healthy Infants and Toddlers in Europe (PHASE3)
- The Effect of Fractional Doses of Pneumococcal Conjugate Vaccines on Immunogenicity and Carriage in Kenyan Infants (PHASE4)
- Persistence of Immunogenicity Following Reduced PCV Dosing Schedules in South African Children
- Evaluation of the Non-Inferiority of a 12-Valent Pneumococcal Conjugate Vaccine in Healthy Children in Brazil. (PHASE3)
- Trial of Pneumococcal Vaccine Schedules in Ho Chi Minh City, Vietnam (PHASE2, PHASE3)
- Study of 10-valent Pneumococcal Conjugate Vaccine (Pneumosil) Administered in a 2+1 Schedule to Healthy Infants (PHASE3)
- Primary Vaccination With Either Synflorix™ or Prevenar 13™ or Both Vaccines and Booster Vaccination With Synflorix™ (PHASE3)
- Post-marketing Safety Evaluation of Pneumococcal Vaccines Among Children and Elderly Adults.
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Prevenar 13 and Synflorix CI brief — competitive landscape report
- Prevenar 13 and Synflorix updates RSS · CI watch RSS
- Papua New Guinea Institute of Medical Research portfolio CI